The Impact of COVID-19 on Cancer Clinical Trials Conducted by NCI-Designated Comprehensive Cancer Centers | Journal of Immunotherapy and Precision Oncology
Skip Nav Destination Article navigation Brief Report| November 13 2020 …
Skip Nav Destination Article navigation Brief Report| November 13 2020 …
The 2024 ASCO Annual Meeting is the most significant gathering of oncology professionals worldwide, making connections and forging collaborations that can
Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant…
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Jennifer M. Ahlstrom HealthTree Foundation, Lehi, UT Jennifer M. Ahlstrom, Dee Lin, Nathan W. Sweeney, Bingcao Wu, Katharine Gries, Nina Kim, Saurabh Patel, Douglas W.…
Despite great treatment advances in multiple myeloma, relapses are frequent and the disease remains a considerable source of morbidity and mortality.1 As treatments advance and…
PURPOSE The study of rare diseases, such as multiple myeloma (MM), often experiences unique research hurdles that can delay or prevent lifesaving discoveries. HealthTree Cure…
Are we ever “done” with myeloma? Jenny Ahlstrom shares her thoughts about heading back into myeloma treatment.
Michael A. Thompson Aurora Cancer Care, Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI Michael A. Thompson, Jenny Ahlstrom, Nathan W. Sweeney Aurora Cancer Care,…
Nathan W. Sweeney HealthTree, Lehi, UT Nathan W. Sweeney, Jenny Ahlstrom, Michael A. Thompson HealthTree, Lehi, UT, CrowdCare Foundation, Draper, UT, Aurora Cancer Care, Aurora…